ConductScience.org, home

Paper38201624

Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer.

Ventura I and 4 others. Cancers (Basel), 2023. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer. Papers, record 38201624. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38201624

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
1.37
iCite
Revised in PubMed
2024-01-14
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ventura IIgnaciohttps://orcid.org/0000-0001-6426-2999
2Sanchiz LLorena
3Legidos-García MEMaría Esterhttps://orcid.org/0000-0001-5468-4434
4Murillo-Llorente MTMaría Teresahttps://orcid.org/0000-0001-9905-0443
5Pérez-Bermejo MMarcelinohttps://orcid.org/0000-0002-5027-4785

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131718044TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.Cells2019https://conductscience.org/library/papers/31718044PubMed
233090190The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.JAMA Oncol2021https://conductscience.org/library/papers/33090190PubMed
335626046Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN).Cancers (Basel)2022https://conductscience.org/library/papers/35626046PubMed
419621070The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.PLoS Med2009https://conductscience.org/library/papers/19621070PubMed
521829019Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis.Dig Dis2011https://conductscience.org/library/papers/21829019PubMed
631439937A global view of hepatocellular carcinoma: trends, risk, prevention and management.Nat Rev Gastroenterol Hepatol2019https://conductscience.org/library/papers/31439937PubMed
731371809Insights into the success and failure of systemic therapy for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2019https://conductscience.org/library/papers/31371809PubMed
833781993PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.BMJ2021https://conductscience.org/library/papers/33781993PubMed
930875085Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening.CA Cancer J Clin2019https://conductscience.org/library/papers/30875085PubMed
1036482887Identification of subtypes of hepatocellular carcinoma and screening of prognostic molecular diagnostic markers based on cell adhesion molecule related genes.Front Genet2022https://conductscience.org/library/papers/36482887PubMed
1134902530Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol2022https://conductscience.org/library/papers/34902530PubMed
1234424422Immunotherapy in Hepatocellular Carcinoma.Curr Treat Options Oncol2021https://conductscience.org/library/papers/34424422PubMed
1336727247The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials.JBI Evid Synth2023https://conductscience.org/library/papers/36727247PubMed
1425173969Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm.J Hepatol2015https://conductscience.org/library/papers/25173969PubMed
1533538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
1632710922Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.J Hepatol2020https://conductscience.org/library/papers/32710922PubMed
1736148739Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.Eur J Cancer2022https://conductscience.org/library/papers/36148739PubMed
1822992590TGFβ signalling in context.Nat Rev Mol Cell Biol2012https://conductscience.org/library/papers/22992590PubMed
1931830641Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma.Cancer Treat Rev2020https://conductscience.org/library/papers/31830641PubMed
2033007432Immunotherapy for advanced hepatocellular carcinoma, where are we?Biochim Biophys Acta Rev Cancer2020https://conductscience.org/library/papers/33007432PubMed

See all 38 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
42353339Deubiquitinating Enzymes as Therapeutic Candidates in Hepatocellular Carcinoma and Other Liver Disease.Int J Mol Sci2026https://conductscience.org/library/papers/42353339PubMed
42272946Current Therapeutic Strategies, Recent Advances and the Emerging Potential of Natural Products in Hepatocellular Carcinoma.Scientifica (Cairo)2026https://conductscience.org/library/papers/42272946PubMed
41804306Endoscopic Innovation Treatment Strategy in Hepatocellular Carcinoma (HCC) Patients Before Immunotherapy: A Case Series Study in Unselected Patients.JGH Open2026https://conductscience.org/library/papers/41804306PubMed
41796277Serum biomarkers as personalised medicine for diagnostic and therapeutic approaches of hepatocellular carcinoma.J Egypt Natl Canc Inst2026https://conductscience.org/library/papers/41796277PubMed
40950361Mechanistic insights into the anti-tumor effects of neochlorogenic acid in hepatocellular carcinoma: in vitro and in vivo studies.J Gastrointest Oncol2025https://conductscience.org/library/papers/40950361PubMed
40928680Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma.Mol Divers2026https://conductscience.org/library/papers/40928680PubMed
40445470Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions.Discov Oncol2025https://conductscience.org/library/papers/40445470PubMed
40395491Atezolizumab Plus Bevacizumab Combined with or without Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study.J Hepatocell Carcinoma2025https://conductscience.org/library/papers/40395491PubMed
40144486Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies.World J Clin Cases2025https://conductscience.org/library/papers/40144486PubMed
40061962Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database.Front Pharmacol2025https://conductscience.org/library/papers/40061962PubMed
40010999Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.In Vivo2025https://conductscience.org/library/papers/40010999PubMed
38398229Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma.Cancers (Basel)2024https://conductscience.org/library/papers/38398229PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174NCBI Gene
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
TGFB17040PubTator's text mininghttps://conductscience.org/library/genes/7040NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38201624

GET https://conductscience.org/api/papers/v1/38201624/references?page=2